Doug J. Bartels

1.8k total citations · 1 hit paper
26 papers, 1.4k citations indexed

About

Doug J. Bartels is a scholar working on Infectious Diseases, Hepatology and Epidemiology. According to data from OpenAlex, Doug J. Bartels has authored 26 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Infectious Diseases, 18 papers in Hepatology and 15 papers in Epidemiology. Recurrent topics in Doug J. Bartels's work include Hepatitis C virus research (18 papers), HIV/AIDS drug development and treatment (18 papers) and Hepatitis B Virus Studies (10 papers). Doug J. Bartels is often cited by papers focused on Hepatitis C virus research (18 papers), HIV/AIDS drug development and treatment (18 papers) and Hepatitis B Virus Studies (10 papers). Doug J. Bartels collaborates with scholars based in United States, Belgium and Germany. Doug J. Bartels's co-authors include Tara L. Kieffer, Ann D. Kwong, Chao Lin, Yi Zhou, Ann M. Tigges, Brian L. Hanzelka, Ute Müh, Hui‐May Chu, Eileen Z. Zhang and David A. Mitchell and has published in prestigious journals such as Journal of Biological Chemistry, Gastroenterology and PLoS ONE.

In The Last Decade

Doug J. Bartels

25 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor Telaprevir

2007 476 citations Christoph Sarrazin, Tara L. Kieffer et al. Gastroenterology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Doug J. Bartels United States	13	1.2k	975	644	208	101	26	1.4k
Linda Bartholomew Italy	11	668 0.5×	505 0.5×	364 0.6×	237 1.1×	33 0.3×	14	962
Gabrielle Vièyres Germany	20	883 0.7×	663 0.7×	182 0.3×	296 1.4×	113 1.1×	31	1.4k
Nicole Krieger Germany	6	1.3k 1.1×	1.0k 1.1×	144 0.2×	277 1.3×	81 0.8×	6	1.5k
Alessandra Ceccacci Italy	7	478 0.4×	357 0.4×	275 0.4×	146 0.7×	39 0.4×	7	677
Lucie Goueslain France	7	489 0.4×	424 0.4×	97 0.2×	170 0.8×	94 0.9×	7	789
Christophe Hourioux France	19	727 0.6×	815 0.8×	194 0.3×	217 1.0×	22 0.2×	32	1.1k
Marie-Anne Petit France	18	589 0.5×	612 0.6×	102 0.2×	198 1.0×	29 0.3×	35	968
Rosa Maria Roccasecca United States	8	927 0.7×	735 0.8×	53 0.1×	342 1.6×	153 1.5×	8	1.3k
Martin Lechmann Germany	15	599 0.5×	439 0.5×	99 0.2×	269 1.3×	93 0.9×	30	1.1k
Tanja B. Jensen Denmark	15	1.2k 1.0×	1.1k 1.1×	138 0.2×	174 0.8×	62 0.6×	18	1.3k

Countries citing papers authored by Doug J. Bartels

Since Specialization

Citations

This map shows the geographic impact of Doug J. Bartels's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Doug J. Bartels with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Doug J. Bartels more than expected).

Fields of papers citing papers by Doug J. Bartels

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Doug J. Bartels. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Doug J. Bartels. The network helps show where Doug J. Bartels may publish in the future.

Co-authorship network of co-authors of Doug J. Bartels

This figure shows the co-authorship network connecting the top 25 collaborators of Doug J. Bartels. A scholar is included among the top collaborators of Doug J. Bartels based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Doug J. Bartels. Doug J. Bartels is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bartels, Doug J., et al.. (2024). WS10.04 CF ferrets exposed to in utero ivacaftor do not develop lens abnormalities. Journal of Cystic Fibrosis. 23. S19–S19. 2 indexed citations

Haseltine, Eric L., Sandra De Meyer, Inge Dierynck, et al.. (2014). Modeling Viral Evolutionary Dynamics after Telaprevir-Based Treatment. PLoS Computational Biology. 10(8). e1003772–e1003772. 6 indexed citations

Jiang, Min, Eileen Z. Zhang, Ann M. Tigges, et al.. (2014). Genotypic and Phenotypic Analyses of Hepatitis C Virus Variants Observed in Clinical Studies of VX-222, a Nonnucleoside NS5B Polymerase Inhibitor. Antimicrobial Agents and Chemotherapy. 58(9). 5456–5465. 16 indexed citations

Sullivan, James C., Sandra De Meyer, Doug J. Bartels, et al.. (2013). Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials. Clinical Infectious Diseases. 57(2). 221–229. 114 indexed citations

Zhang, Eileen Z., Doug J. Bartels, J. Daniel Frantz, et al.. (2013). Development of a sensitive RT-PCR method for amplifying and sequencing near full-length HCV genotype 1 RNA from patient samples. Virology Journal. 10(1). 53–53. 22 indexed citations

Jiang, Min, Nagraj Mani, Chao Lin, et al.. (2013). In Vitro Phenotypic Characterization of Hepatitis C Virus NS3 Protease Variants Observed in Clinical Studies of Telaprevir. Antimicrobial Agents and Chemotherapy. 57(12). 6236–6245. 25 indexed citations

Sullivan, James C., Eileen Z. Zhang, Doug J. Bartels, et al.. (2012). Compensatory substitutions in the HCV NS3/4A protease cleavage sites are not observed in patients treated unsuccessfully with telaprevir combination treatment. Virology Journal. 9(1). 147–147. 1 indexed citations

Kieffer, Tara L., Sandra De Meyer, Doug J. Bartels, et al.. (2012). Hepatitis C Viral Evolution in Genotype 1 Treatment-Naïve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials. PLoS ONE. 7(4). e34372–e34372. 74 indexed citations

Adda, Nathalie, Doug J. Bartels, Linda Gritz, et al.. (2012). Futility Rules for Telaprevir Combination Treatment for Patients With Hepatitis C Virus Infection. Clinical Gastroenterology and Hepatology. 11(2). 193–195. 8 indexed citations

10.

Bartels, Doug J., Linda Gritz, Tara L. Kieffer, et al.. (2012). 55 FUTILITY RULES IN TELAPREVIR COMBINATION TREATMENT. Journal of Hepatology. 56. S24–S24. 11 indexed citations

11.

Bartels, Doug J., James C. Sullivan, Eileen Z. Zhang, et al.. (2012). Hepatitis C Virus Variants with Decreased Sensitivity to Direct-Acting Antivirals (DAAs) Were Rarely Observed in DAA-Naive Patients prior to Treatment. Journal of Virology. 87(3). 1544–1553. 121 indexed citations

12.

Picchio, Gastón, C. Sarrazin, H.W. Reesink, et al.. (2012). T-24 Retreatment with telaprevir/Peg-IFN/RBV after a short exposure to telaprevir in Phase I studies: interim results from a Phase IIIb rollover trial (C219). Digestive and Liver Disease. 44. S22–S22. 6 indexed citations

13.

Adiwijaya, Bambang S., Tara L. Kieffer, Doug J. Bartels, et al.. (2011). Modeling, Clinical and Virology Data From Phase 2 and 3 Studies Support 12-Week Telaprevir Duration in Combination With 24- or 48-Week Peginterferon/Ribavirin. Gastroenterology. 140(5). S–943. 1 indexed citations

14.

Ahmed‐Belkacem, Abdelhakim, Stéphane Chevaliez, Alexandre Soulier, et al.. (2010). Characterization of V36C, a Novel Amino Acid Substitution Conferring Hepatitis C Virus (HCV) Resistance to Telaprevir, a Potent Peptidomimetic Inhibitor of HCV Protease. Antimicrobial Agents and Chemotherapy. 54(6). 2681–2683. 11 indexed citations

15.

Bartels, Doug J., Yi Zhou, Eileen Z. Zhang, et al.. (2008). Natural Prevalence of Hepatitis C Virus Variants with Decreased Sensitivity to NS3·4A Protease Inhibitors in Treatment‐Naive Subjects. The Journal of Infectious Diseases. 198(6). 800–807. 162 indexed citations

16.

Bartels, Doug J., Yi Zhou, Randal A. Byrn, et al.. (2008). 843 NATURAL PREVALENCE OF HCV VARIANTS WITH DECREASED SUSCEPTIBILITY TO NS3-4A PROTEASE INHIBITORS IN TREATMENT-NAIVE SUBJECTS. Journal of Hepatology. 48. S316–S316. 5 indexed citations

17.

Zhou, Yi, Brian L. Hanzelka, Doug J. Bartels, et al.. (2007). Phenotypic and Structural Analyses of Hepatitis C Virus NS3 Protease Arg155 Variants. Journal of Biological Chemistry. 282(31). 22619–22628. 71 indexed citations

18.

Sarrazin, Christoph, Tara L. Kieffer, Doug J. Bartels, et al.. (2007). Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor Telaprevir. Gastroenterology. 132(5). 1767–1777. 476 indexed citations breakdown →

19.

Hanzelka, Brian L., Ute Müh, Ladislau C. Kovari, et al.. (2007). [12] TELAPREVIR (VX-950) IS A POTENT INHIBITOR OF HCV NS3 PROTEASES DERIVED FROM GENOTYPE NON-1 HCV-INFECTED PATIENTS. Journal of Hepatology. 46. S8–S8. 7 indexed citations

20.

Bartels, Doug J., et al.. (1999). Erf2, a Novel Gene Product That Affects the Localization and Palmitoylation of Ras2 in Saccharomyces cerevisiae. Molecular and Cellular Biology. 19(10). 6775–6787. 152 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact